AURORA, ON, Jan. 10 /PRNewswire-FirstCall/ - Helix BioPharma Corp.
Institutional Shareholder Services (“ISS”) has recommended that shareholders use management’s YELLOW proxy form to vote their shares at Helix’s Annual General and Special Meeting on January 23, 2007 in favour of management’s slate of directors and for the resolution approving the issuance of shares in a private placement. ISS recommends that shareholders DO NOT VOTE the blue dissident proxy.
ISS is widely recognized as the world’s leading provider of proxy voting and corporate governance solutions to the institutional marketplace. Its analyses and recommendations are relied upon by 1,712 institutional investment firms, mutual funds and fiduciaries worldwide.
ISS spoke to both Management and the dissident before recommending that shareholders vote for the Management nominees. Any shareholder seeking the advice of a knowledgeable and independent third party should consider the ISS recommendation.
ISS has also recommended that shareholders vote in favour of the private placement and has noted in their analysis that the private placement is in the ordinary course of business and in compliance with TSX rules.
Helix’s board of directors and management are extremely pleased that ISS recommends that shareholders vote for Management’s nominees on the YELLOW proxy form.
------------------------------------------------------------------------- DISCARD ANY BLUE PROXIES AND VOTING FORMS sent by the dissident ------- IF YOU HAVE ALREADY VOTED A BLUE PROXY FORM, CHANGE YOUR VOTE NOW PLEASE SIGN, DATE AND RETURN YOUR YELLOW proxy as soon as possible ------ ------------------------------------------------------------------------- For more information and assistance in completing your YELLOW proxy form, please call Georgeson, Helix’s proxy solicitor: North American toll free number 1-866-288-9745 European(x) toll free number 00800-1020-1010 Collect calls outside North America can be made at +1-416-642-7018 or +44(0)117-378-5993
A copy of Helix BioPharma’s current Annual Report and Management Information Circular for the January 23, 2007 meeting can be found on SEDAR at www.sedar.com, and at Helix’s website at www.helixbiopharma.com. Requests for a hard copy of the Annual Report or Management Information Circular can also be made to Georgeson. For more information call Georgeson, Helix’s proxy solicitor at:
Georgeson North American Toll Free Number: 1-866-288-9745 Outside North America Collect: +1-416-642-7018 ((x))Toll Free - European: 00800 1020 1010 European Collect: +44 (0) 117 378 5993 ((x))Australia; Austria; Belgium; Denmark; Finland; France; Germany; Hong Kong; Ireland; Israel; Italy; Netherlands; New Zealand; Norway; Spain; Sweden; Switzerland; Thailand; United Kingdom Please visit our website for regular updates at www.helixbiopharma.com
This document contains certain forward-looking information and statements regarding the Company’s upcoming Annual General and Special Meeting.
Forward-looking information and statements are not historical facts but are predictions about the future and are inherently uncertain. Forward-looking information and statements can be identified by the use of future dates and forward-looking terminology such as “recommends”, or comparable terminology referring to future events or results, or that events or conditions “will” occur or be achieved, or comparable terminology referring to future events or results.
The Company’s actual results could differ materially from a conclusion, forecast or projection in its forward-looking information and statements due to a variety of risks, uncertainties and other factors, including, without limitation: the possibility that the January 23, 2007 meeting may be adjourned or postponed; uncertainty as to the outcome of the January 23, 2007 shareholders meeting; uncertainty whether the Company will be able to complete any financing on the terms proposed or at all; uncertainty whether any of the Company’s proposed drug products will be successfully developed or at all; research and development risks; and other factors that are discussed or identified in the Company’s latest Annual Information Form filed on SEDAR at www.sedar.com any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Forward-looking statements are based on the assumptions, beliefs, opinions and expectations of the Company’s management at the time they are made, and the Company does not assume any obligation to update its forward-looking statement if those assumptions, beliefs, opinions or expectations, or other circumstances should change. For the reasons set forth above, investors should not place undue reliance on forward-looking statements. The Company does not assume any obligation to update any statement contained in this document.
Helix BioPharma Corp.
CONTACT: Georgeson, Helix’s proxy solicitor, at their North American tollfree number 1-866-288-9745, or European(x) toll free number00800-1020-1010; Collect calls outside North America can be made at (416)642-7018 or +44(0)117-378-5993